SCHEDULE 13D

CUSIP No.

433000106

Name of reporting person

Andrew Dudum

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

SC, PF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 23,820,905.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 23,820,905.00
10	Shared Dispositive Power 0.00

Aggregate amount beneficially owned by each reporting person

23,820,905.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

10.3 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person:

1. Includes (i) 9,333,039 shares of Class A Common Stock held by trusts affiliated with the Reporting Person, (ii) 92,313 shares of Class A Common Stock held directly by the Reporting Person, (iii) 8,377,623 shares of Class V Common Stock held by trusts affiliated with the Reporting Person, (iv) 164,368 shares of Class A Common Stock underlying restricted stock units expected to settle within 60 days, (v) 5,643,186 shares of Class A Common Stock underlying stock options exercisable within 60 days of the date of this Schedule 13D held by the Reporting Person, (vi) 80,023 shares of Class A Common Stock underlying stock options that are not exercisable within 60 days of the date of this Schedule 13D, but which are subject to service-based vesting over a four-year period, with approximately 4,468 options vesting per month through April 2027, and (vii) 130,353 shares of Class A Common Stock underlying stock options that are not exercisable within 60 days of the date of this Schedule 13D, but which are subject to service-based vesting over a four-year period, with approximately 21,725 options vesting per month through March 2026. Excludes 1,296,568 shares of Class A Common Stock underlying restricted stock units not expected to settle within 60 days. 2. All shares of Class V Common Stock will convert automatically into an equal number of shares of Class A Common Stock (i) upon any transfer of shares of Class V Common Stock, with limited exceptions and (ii) upon adoption of a resolution by the Board at any time on or after the one-year anniversary of the date that both trigger conditions, as such conditions are described in the Issuer's Certificate of Incorporation, dated as of January 20, 2021, are satisfied. 3. Percentage is calculated based on 231,873,143 shares of Class A Common Stock, which is the sum of (i) 217,641,958 shares of Class A Common Stock of the Issuer outstanding as of August 1, 2025, as reported by the Issuer in its Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on August 4, 2025, plus (ii) 8,377,623 shares of Class V Common Stock of the Issuer outstanding, (iii) 164,368 shares of Class A Common Stock underlying restricted stock units expected to settle within 60 days, (iv) 5,643,186 shares of Class A Common Stock underlying stock options held by the Reporting Person that are exercisable within 60 days of the date of this Schedule 13D, and (v) 210,376 shares of Class A Common Stock underlying stock options held by the Reporting Person that are not exercisable within 60 days of the date of this Schedule 13D. The Reporting Person beneficially owns 10.3% of the outstanding shares of Class A Common Stock (assuming exercise of all outstanding stock options and conversion of all outstanding shares of Class V held by the Reporting Person) and 100% of the outstanding Class V Common Stock.

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Class A common stock, $0.0001 par value per share

(b)

Name of Issuer:

Hims & Hers Health, Inc.

(c)

Address of Issuer's Principal Executive Offices:

2269 Chestnut Street, #523, San Francisco, CALIFORNIA , 94123.

Item 1 Comment:

This Amendment No. 3 to Schedule 13D relates to the Class A Common Stock, $0.0001 par value per share (Class A Common Stock) of Hims & Hers Health, Inc. (Issuer), and amends and supplements the initial statement on Schedule 13D filed by the Reporting Person with the Commission on February 1, 2021, as amended by Amendment No. 1 filed with the Commission on December 15, 2021 and Amendment No. 2 filed with the Commission on October 25, 2024 (collectively, the Original Schedule 13D and, as so amended and supplemented, the Statement). This Statement is being filed by the Reporting Person. Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 3 have the meanings ascribed to them in the Original Schedule 13D.

Item 2.

Identity and Background

(a)

Andrew Dudum, an individual ( "Reporting Person").

(b)

The business address of Reporting Person is c/o Hims & Hers Health, Inc., 2269 Chestnut Street, #523, San Francisco, California, 94123.

(c)

The Reporting Person is the Chief Executive Officer and a member of the Board of Directors of the Issuer.

(d)

During the last five years, Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)

During the last five years, Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding has been or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)

The Reporting Person is a citizen of the United States of America.

Item 3.

Source and Amount of Funds or Other Consideration

The information set forth in Item 3 of the Original Schedule 13D is incorporated herein by reference.

Item 4.

Purpose of Transaction

The information set forth in Item 4 of the Original Schedule 13D is incorporated herein by reference.

Item 5.

Interest in Securities of the Issuer

(a)

See Items 7-11 of the cover pages of this Amendment No. 1.

(b)

See Items 7-11 of the cover pages of this Amendment No. 1.

(c)

The transactions in the securities of the Issuer by the Reporting Person since the sixtieth day prior to the date of the event requiring the filing of this Amendment No. 3 are set forth in Schedule A hereto and are incorporated herein by reference.

(d)

To the best knowledge of the Reporting Person, no person other than the Reporting Person or his affiliated trusts has the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of the shares of Class A Common Stock reported herein.

(e)

Not applicable

Item 6.

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

The information set forth in Item 6 of the Original Schedule 13D is incorporated herein by reference.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Andrew Dudum

Signature:	/s/ Alexandra Cotter Wilkins, as Attorney-in-Fact for Andrew Dudum
Name/Title:	Andrew Dudum
Date:	08/13/2025